Insmed Incorporated Q3 2025 Earnings Recap

Insmed reported a strong start to the commercial launch of BRINSUPRI, reflecting positive physician and patient reception, although only 6 weeks of sales data is currently available.

Key Takeaways

• BRINSUPRI's launch indicates a robust initial prescription breadth, positioning it among notable respiratory therapies.
• The European approval process for brensocatib is progressing, with potential EU launch anticipated in early 2026.
• Upcoming key clinical milestones include results from the Phase II BiRCh study for CRS without nasal polyps by early January 2026.
• Insmed maintains an ambitious pipeline with multiple catalysts expected over the next 18 months, enhancing growth prospects in the market.